Babaodan

also known as BBD

Developed for: hepatocellular carcinoma · radiation pneumonitis
Investigated by: Eastern Hepatobiliary Surgery Hospital · Fifth Affiliated Hospital, Sun Yat-Sen University · First Affiliated Hospital, Sun Yat-Sen University · Meng Chao Hepatobiliary Hospital of Fujian Medical University · Second Military Medical University · Shanghai Zhongshan Hospital
+3 more
· Sun Yat-sen University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Xiamen Traditional Chinese Medicine Co., Ltd.

today NCT06079931 · Ph 2 NCT03515369 · Ph 4

201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT06079931	Dec 2024 → Sep 2025	radiation pneumonitis	Fifth Affiliated Hospital, Sun Yat-Sen University	Unknown	No outcome recorded
Phase 41 trial
Phase 4	NCT03515369	May 2018 → Jan 2022	hepatocellular carcinoma	Eastern Hepatobiliary Surgery Hospital	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Babaodan	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06079931 ↗ 1 NCT03515369 ↗
Known as	BBD	“traditional Chinese patent Babaodan (BBD) capsule has the effect of controlling macrophages to produce proinflammatory cytokines, such as significantly inhibiting the release of IL-6.” NCT06079931 ↗
Action	Inhibit	“Babaodan can inhibit LPS-induced HSCs activation and proliferation in vitro” NCT03515369 ↗
Modality	Traditional medicine (herbal / TCM)	“traditional Chinese medicine Babaodan” NCT03515369 ↗
Route	Oral	“take Babaodan oral capsule within 4 weeks after curative resection” NCT03515369 ↗
Target	IL6	“significantly inhibiting the release of IL-6” NCT06079931 ↗